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Abstract
This study proposes an effective positive control design strategy for cancer treatment by resorting
to the combination of immunotherapy and chemotherapy. The treatment objective is to transfer the
initial number of tumor cells and immune–competent cells from the malignant region into the region
of benign growth where the immune system can inhibit tumor growth. In order to achieve this goal,
a new modeling strategy is used that is based on Takagi–Sugen. A Takagi-Sugeno fuzzy model is
derived based on the Stepanova nonlinear model that enables a systematic design of the controller.
Then, a positive Parallel Distributed Compensation controller is proposed based on a linear co-
positive Lyapunov Function so that the tumor volume and administration of the chemotherapeutic
and immunotherapeutic drugs is reduced, while the density of the immune-competent cells is reached
to an acceptable level. Thanks to the proposed strategy, the entire control design is formulated as
a Linear Programming problem, which can be solved very efficiently. Finally, the simulation results
show the effectiveness of the proposed control approach for the cancer treatment.
Keywords: Co-positive linear Lyapunov function, Cancer, Chemotherapy, Immunotherapy,
Positive system, Takagi–Sugeno fuzzy system.
1. Introduction
After cardiovascular disease, cancer is the most common cause of death in the world [1]. There
are several therapies for the cancer treatment such as surgery, immunotherapy, radiotherapy, and
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chemotherapy. It is noticeable that even when the treatment is completed, there is still a possibility
of the disease. For this reason, many researchers have studied the cancer models, aiming to find a
definitive cancer treatment [2, 3, 4]. In the literature, chemotherapy is the most common way for
the cancer treatment. In some cases, chemotherapy is the only treatment. However chemotherapy
is mostly used along with other treatments, the main reasons for this are described as follows: i)
cancer cells tend to grow fast, and chemotherapy drugs kill fast-growing cells. Since these drugs
travel throughout the body, they can also affect normal and healthy cells that are fast-growing.
Therefore, damage to healthy cells is the main side effect of the chemotherapy. ii) cancer cells
are deforming in order to survive while under treatment, and for this reason, the chemotherapy
treatment is often stopped. In the last few decades, immunotherapy has become an important part
of treating some types of cancers [5]. This treatment uses the body’s own immune system to cure
cancer with fewer side effects compared to the chemotherapy treatment. As a result, the optimal
way to blend manifold cancer treatments remains an open problem.
Abundant efforts have been devoted to study the dynamics and interactions of the tumor and
normal cells aiming to design appropriate control strategies, such that the tumor cells are eradicated
as much as possible without harming the healthy cells. Stepanova [6] suggested a mathematical
model for expressing the interactions between the tumor and immune system. This model, in spite
of its simplicity, and with a small number of parameters, plays an important role in resembling
tumor-immune interactions. In [7], a metamodel for tumor-immune system interactions has been
proposed, where the treatment has been formulated as an optimal control problem by cytotoxic
agents and immunostimulations. In [8], a multi-objective optimal control of a tumor growth model
with the immune response and drug therapies has been presented, so that the average number of
tumor cells and immuno and chemotherapeutic drugs administration are minimized at the same
time. In [9], a comparison has been made by means of an optimal strategy to control the dynamics
of three tumor growth models that consist of an immune system and drug administration therapy.
Up to now, most of the control strategies are based on minimizing the drug dosage in an
open-loop mode using an optimal control approach. Model predictive control (MPC) has been
applied as an effective strategy for the cancer chemotherapy [10]. Blended immunotherapy and
chemotherapy for tumor treatment using MPC has been proposed in [11]. The Kirschner model
has been proposed in [12], and adopted to design an adaptive fuzzy back-stepping control strategy
for the tumor-immune system in [13]. The purpose of this work is to develop an effective treatment
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plan for the drug dosage to reduce the volume of tumor cells. However, this case only covers cancer
immunotherapy.
In the past two decades, significant advances have been made for the control of nonlinear sys-
tems. Takagi–Sugeno (T–S) fuzzy models have widely used in the control community to design
nonlinear control strategies [14, 15, 16]. This model consists of a convex combination of several
linear subsystems and nonlinear membership functions in the form of IF-THEN rules, which are
considered as a universal approximator for nonlinear dynamics.
This work considers the reformed Stepanova model for the cancer-immune system interactions.
Although this model is a simple and basic model, it includes many important medical features. The
state variables in this model involve quantities that have non-negative signs. This model belongs to
a significant class of systems known as “Positive Systems”. In such systems, the state variables that
correspond to any non-negative initial states always have to be non-negative [17, 18]. In addition,
the positive systems states are defined inside a cone situated in the positive orthant instead of
the whole space. Such systems have several applications in controlling chemical processes, biology,
medicine, and economics systems [19].
This paper is a mixture of immunotherapy and chemotherapy for the cancer treatment. The
purpose of this research is to design a positive T–S fuzzy controller for an appropriate and efficient
treatment, in which the combination of tumor volume as well as the potential side effects are
reduced, and, consequently, the density of immune–competent cells is reached to an admissible
level. Simulation results show the effectiveness of the proposed method, which can help to develop
mixed therapies. Compared to the state-of-the-art approaches, it is observed that during this
treatment the maximum number of cancer cells and the side effects are significantly reduced.
The main contributions of this paper can be summarized as follows: a new fuzzy modeling
framework, which exactly represents the nonlinear system, is proposed, which reduces the number
of fuzzy rules that inherently affect the conservatism. Then, a parallel distributed compensation
(PDC) is derived as a naive and reliable method to handle nonlinear control systems. The con-
cept of a dual system is also employed. The previous methods to stabilize the positive systems
use a quadratic Lyapunov function that is imposed to be diagonal, and, consequently, increases
conservatism. Here, a linear co-positive Lyapunov function (LCPLF) is proposed. The obtained
results are expressed in terms of linear programming (LP) that leads to more convenient conditions
for computation and analysis compared to the existing ones. However, the fuzzy model cannot
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be easily extracted from the reformed Stepanova model due to the existence of a constant term
in the nonlinear model. To cope with this problem, this approach considers the control input has
two parts; one part of this control agent eliminates some nonlinear terms, and the other part is
responsible for the stability of the remaining nonlinear system.
The rest of the paper is organized as follows: The Stepanova model of the tumor-immune system
is described in Section 2. The proposed fuzzy modeling framework and the proposed control method
for the positive T–S system are presented in Section 3. The simulation results are presented in
Section 4. Section 5 concludes the paper.
Notations: Rn represents a set of n-column real vectors, and Rn×m is a set of n × m real
matrix. The notation A ≥≥ B (respectively, A≫ B) means that the matrix A−B is element-wise
nonnegative (respectively, A−B is element-wise positive). 1 = [1, 1, ..., 1]T denotes a column vector,
in which all entries are equal to 1. The superscript ‘T ’ stands for the transpose operator; I and 0
represent the identity and zero matrices, respectively; diag(A1, ..., An) represents a block diagonal
matrix, in which A1, ..., An are square matrices along the main diagonal.
2. Stepanova Model
In this section, the Stepanova mathematical model that expresses the interactions between the
immune and tumor system is introduced [6]. Here the Stepanova model is used to describe the tumor
growth with an immune response, immunotherapy, and chemotherapy. To clarify this subject, one
can consider the reformed form of the Stepanova model as follows [7]:
x˙1(t) = µcx1(t)F (x1)− γx1(t)x2(t)− kx1x1(t)u1(t) (1)
x˙2(t) = µI(x1(t)− βx
2
1(t))x2(t)− δx2(t) + α+ kx2x2(t)u2(t) (2)
where x1(t) and x2(t) indicate the number of tumor cells and effector cells of the immune system,
respectively. The control agent u1(t) denotes the blood profiles of a cytotoxic agent and u2(t)
indicates the immune system booster drug for the immune cells in the cancer treatment. kx1 and
kx2 stand for the maximum dose rates of the therapeutic agents.
Equation (1) models tumor growth, where µc denotes the tumor growth coefficient and the
coefficient γ shows the rate at which cancer cells are eliminated. The term γx1x2 models the useful
effect of the immune response on the cancer volume. F is a function of the growth of the tumor cells
and there are various selections that can be considered for that. However, here the Gompertz growth
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function [20] in the form of F (x1) = −ln(
x1(t)
x∞
) is considered instead of other growth functions such
as exponential model or logistic or generalized logistic growth. In this function, x∞ is the fixed
finite carrying capacity of the tumor.
Equation (2) models the main specifications of the immune systems response to the tumor cells.
The effect of the tumor growth on the activity of immune cells is shown by the first term. The
coefficients µI , β and δ are the tumor stimulated proliferation rate, the inverse threshold for tumor
suppression and the rate of natural death of immune cells, respectively. α represents the rate of
influx of the effector cells from the primary organs.
Equilibrium point: The determination of the equilibrium points and analyzing systems be-
havior around these points play a significant role in dynamical systems. Stopping the growth and
moving process in these points are some of the most important reasons behind this subject. Al-
though this is not suitable for some physical processes such as motion, it can be an ideal solution
for some medical applications, such as tumor growth [21].
When the patient’s body system reaches a point, in which the number of tumor cells is zero
or very low, the treatment is completed. The unforced system without medication has two locally
asymptotically stable equilibriums, which can be obtained by solving the equations x˙1(t) = 0 and
x˙2(t) = 0, one microscopic point at (72.961, 1.32), which is the region of attraction corresponding to
the benign conditions (where the number of tumor cells is low) and the other is macroscopic point
at (737.278, 0.032), which is the region of attraction related to the malignant situations, where the
number of tumor cells is high. These regions of attraction are separated by a stable manifold of an
intermediate saddle point at (356.2, 0.439).
It is obvious that for any model of cancer, the states x1(t) and x2(t) should remain positive for
the positive initial conditions x1(0) and x2(0), and arbitrary acceptable controls u1(t) and u2(t).
Therefore, the nonlinear model mentioned for cancer, based on the interaction between the tumor
cells and the immune cells, can be considered as a positive system. Therefore, a set κ that can be
defined as follow is a positive invariant set for the above model, and, then, no positive constraints
imposed to variables:
κ = {(x1, x2) : x1 > 0, x2 > 0} .
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3. Positive T-S Fuzzy Modeling and Controller design
In this section, first, a new fuzzy modeling framework for the nonlinear model of the cancer
treatment is proposed so that the number of fuzzy rules is reduced. Next, the stability and new LP
conditions for the controller design of positive T–S systems are proposed.
3.1. Fuzzy Modeling
To obtain a T–S fuzzy representation of Eqs. (1) and (2), the nonlinear terms of the model are
considered as premise variables. Denote ϑ1 = −µcln(
x1
x∞
), ϑ2 = −γx1, ϑ3 = µI(x1 − βx
2
1) − δ,
ϑ4 = −kx1x1 and, ϑ5 = kx2x2. Therefore, the corresponding model is given by:

x˙1 = ϑ1x1 − ϑ2x2 − ϑ4u1
x˙2 = ϑ3x2 + α+ ϑ5u2.
(3)
Because of the existence of a constant term α in the second equation, the fuzzy model cannot be
easily extracted from the system (3). To overcome this problem, an approach is suggested, which
is based on the change of variable. For this purpose, the control input consists of two parts: i)
one part is used to eliminate some nonlinear terms of equations; ii) another part is considered to
stabilize the reminding nonlinear dynamical model. This approach has two main advantages; First,
a T–S fuzzy model can be extracted directly from nonlinear equations of the system, and secondly,
the number of fuzzy rules is reduced that leads to less conservatism. Accordingly, the new control
input vector is defined as follows:
u∗2 = α+ kx2x2u2 → u2 =
u∗2 − α
kx2x2
(4)
Therefore, the equations (1) and (2) can be rewritten as follows:


x˙1 = −µcx1ln(
x1
x∞
)− γx1x2 − kx1x1u1,
x˙2 = µI(x1 − βx
2
1)x2 − δx2 + u
∗
2.
(5)
By defining the nonlinear terms as ϑ¯1 = −µcln(
x
x∞
)− γy, ϑ¯2 = −µI(x−βx
2)− δ and, ϑ¯3 = −kxx,
then the general form of the Eq.(5) is as follows:


X˙(t) = A(ϑ¯1, ϑ¯2)X(t) +B(ϑ¯3)U(t),
z(t) = CX(t),
(6)
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where z(t) is the output vector and we have,
X =

x1
x2

 , A(ϑ¯1, ϑ¯2) =

ϑ¯1 0
0 ϑ¯2

 , B(ϑ¯3) =

ϑ¯3 0
0 1

 , U =

u1
u∗2

 , C = I2 .
In the set point tracking problem, the following integral control structure is used:
eI =
∫
(zr − z)dt
where e = zr − z is the tracking error. The goal is that the output z tracks a given reference zr.
Finally, the augmented system can be defined by the following system:


˙¯X(t) = A¯(ϑ¯1, ϑ¯2)X¯ + B¯(ϑ¯3)U + D¯Zr,
z(t) = C¯X¯.
(7)
where
X¯ =

X
eI

, A¯(ϑ¯1, ϑ¯2) =

A(ϑ¯1, ϑ¯2) 0
−C 0

 , B¯(ϑ¯3) =

B(ϑ¯3)
0

 ,
C¯ =
[
C 0
]
, D¯ =

0 0
0 I

 , Zr =

 0
zr

 .
By computing the maximum and minimum values of premise variables under x1 ∈ [0, 1000] and
x2 ∈ [0, 5], ϑ¯1, ϑ¯2 and, ϑ¯3 can be described as:
ϑ¯1 = max(ϑ¯1) . M1(ϑ¯1) + min(ϑ¯1) . M2(ϑ¯1),
ϑ¯2 = max(ϑ¯2) . N1(ϑ¯2) + min(ϑ¯2) . N2(ϑ¯2),
ϑ¯3 = max(ϑ¯3) . S1(ϑ¯3) + min(ϑ¯3) . S2(ϑ¯3),
where
M1(ϑ¯1) =
ϑ¯1 −min(ϑ¯1)
max(ϑ¯1)−min(ϑ¯1)
,M2(ϑ¯1) = 1−M1(ϑ¯1)
N1(ϑ¯2) =
ϑ¯2 −min(ϑ¯2)
max(ϑ¯2)−min(ϑ¯2)
, N2(ϑ¯2) = 1−N1(ϑ¯2),
S1(ϑ¯3) =
ϑ¯3 −min(ϑ¯3)
max(ϑ¯3)−min(ϑ¯3)
, S2(ϑ¯3) = 1− S1(ϑ¯3).
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Accordingly, the membership functions are calculated as follows:
h1 =M1 ×N1 × S1, h2 =M1 ×N1 × S2,
h3 =M1 ×N2 × S1, h4 =M1 ×N2 × S2,
h5 =M2 ×N1 × S1, h6 =M2 ×N1 × S2,
h7 =M2 ×N2 × S1, h8 =M2 ×N2 × S2.
It should be noted that the Euler technique is applied for discretization, however, any discretiza-
tion method can also be used by a sampling time T. Hence, the T–S fuzzy model related to the
augmented discrete-time system is presented by 8 linear sub-models:


X¯(k + 1) = A¯diX¯(k) + B¯diU(k) + D¯diZr,
z(k) = C¯X¯(k),
(8)
where i = 1, 2, ..., 8 and matrices A¯di, B¯di and, D¯di, respectively, characterize the discretized
matrices related to A¯i, B¯i and, D¯i.
To validate the newly proposed fuzzy modeling framework, the nonlinear model is simultaneously
simulated with the T–S fuzzy model of the cancer system. The parameters reported in the Table
(1) are used for simulation.
The simulation results in the absence of control by taking an initial condition asX0 =
[
600 0.1
]T
,
is shown in Fig. 1. The tumor volume is in multiples of 106 cells, while the effector cells density
is measured in a scale relative to 1. As can be seen, the behavior of both systems is quite similar
and the T–S fuzzy system exactly models the nonlinear system. Fig. 1 shows that simultaneously
with the growth and proliferation of tumor cells, the density of the immune system cells decreases
significantly. Therefore, these results substantiate the effectiveness of the synthesized fuzzy model
that will be considered in the controller synthesis.
The goal is to design a controller that reduces the tumor volume and also holds the density
of the effector cells at an acceptable level. Therefore, the controller is designed in a way that it
guarantees the states x1 and x2 always remain positive. Then, the linear Lyapunov based method
is used to design the controller that renders nonnegative states, while they do not always exist using
the classical Lyapunov function even with linear matrix inequalities (LMIs).
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Table 1: The values of parameters/variables [7].
Variable/Parameter Descriptions Numerical value Dimension
x1(0) The initial value of x1 600 10
6 cells
x2(0) The initial value of x2 0.1 Non-dimensional
α Rate of influx 0.1181 1/day
β Inverse threshold for tumor suppression 0.00264 Non-dimensional
γ Interaction rate 1 107 cells/day
δ Death rate 0.37451 1/day
µC Tumor growth parameter 0.5599 10
7 cells/day
µI Tumor stimulated proliferation rate 0.00484 10
7 cells/day
x∞ Fixed carrying capacity 780 10
6 cells
k chemotherapeutic killing parameter 1 107 cells/day
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Figure 1: Dynamic profile of the tumor cells and the effector cells’ density.
3.2. Stability Analysis
The control objective of this subsection is to obtain the stability condition for the positive T–S
fuzzy systems. The attained result is presented in the LP framework. Throughout this subsection
it is assumed that the underlying system is unforced that is, u(k) ≡ 0.
Remark 1. A system whose matrices are transposed is called a dual system of another one. It is
significant to note that asymptotic stability of the system (A.2) is equivalent to asymptotic stability
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of its dual [22, 23], i.e,
x(k + 1) =
r∑
i=1
hi(ϑ(k))A
T
i x(k). (9)
Proposition 1. If there exist a vector p ≥≥ 0 such that
(Ai − I)p≪ 0, (10)
holds i = 1, 2, ..., r, then, the system (A.2) is asymptotically stable.
Proof. Given the positive system (9) means x(k) ≥≥ 0 for all k ∈ Rn+. Consider a linear Lyapunov
function candidate as
V (x(k)) = xT (k)p, p ≥≥ 0. (11)
Then the rate of increase of V (x(k)) is given by:
∆V (x(k)) = V (x(k + 1))− V (x(k)),
= xT (k + 1)p− xT (k)p,
=
r∑
i=1
hi(ϑ(k))x
T (k)Aip− x
T (k)p,
=
r∑
i=1
hi(ϑ(k))
(
xT (k)(Ai − I)p
)
< 0, (12)
Since the states of positive systems are nonnegative and 0 ≤ hi(ϑk) ≤ 1 and
∑r
i=1 hi(ϑ(k)) = 1, the
Lyapunov stability condition, ∆V (x(k)) < 0 holds if and only if the inequality (10) is satisfied. The
whole proof is completed. 
As a conclusion, the existence of LCPLF for the dual system (9) ensures the asymptotic stability
of the original system (A.2). It should be noted that the existence of LCPLF for the positive
system (A.2) neither guarantees the existence of such a Lyapunov function for the dual system (9)
nor ensures the correctness of the converse [22]. For example, consider the system (A.2) with two
subsystems and the matrices:
A1 =

1/2 1/2
1/3 1/2

 , A2 =

 1/2 1/2
2/27 2/3

 .
Hence, both A1 and A2 are nonnegative and Schur stable. It is simply seen that no LCPLF can be
found, but the dual system has LCPLF V (x(k)) =
[
4 3
]
x(k).
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3.3. Controller synthesis for the positive T–S fuzzy system
In this subsection, an approach based on the LCPLF and PDC controller is proposed. In this
technique, the concept of the dual system is used and the Lyapunov function V (x(k)) = xT (k)p
is considered to derive the stabilization condition in the form of new LPs. Assuming that the
state variables can directly be measured, the main aim is then to design a state feedback controller
through the PDC structure, which is defined as follows:
u(k) =
r∑
i=1
hi(ϑ(k))Kix(k). (13)
Then, the closed-loop system can be obtained by Substituting (13) into (A.2):
Sc :


x(k + 1) =
r∑
i=1
r∑
j=1
hi(ϑ(k))hj(ϑ(k))(Ai +BiKj)x(k),
z(k) =
r∑
i=1
r∑
j=1
hi(ϑ(k))hj(ϑ(k))(Ci +DiKj)x(k).
(14)
Theorem 1. For the positive fuzzy system (A.2), the state-feedback controller (13) exists such that
the closed-loop system (14) is positive and asymptotically stable if and only if there exist a diagonal
matrix Q ∈ Rn×n and matrix Mj ∈ R
m×n such that the following LP conditions are satisfied:
[(Ai − I)Q+BiMj ]1
n ≪ 0, for i, j = 1, 2, ..., r, (15a)
Q≫ 0, (15b)
Mj ≤≤ 0, for j = 1, ..., r, (15c)
[
ai
]
h t
qt +
r∑
z=1
[
bi
]
h z
[
mj
]
z t
≥≥ 0, for h, t = 1, ..., n. (15d)
where Ai ,
[
ai
]
ht
, Bi , [b
i
1, ..., b
i
n]
T , are given square matrices. Then, the controller gain Kj is
computed by:
Kj =MjQ
−1 ∈ Rm×n. (16)
Proof. Sufficiency: Assume that conditions (15a)-(15c) hold and Kj = [k
j
1, ..., k
j
n] are defined
through kjt = m
j
tqt for j = 1, .., r and t = 1, ..., n. Then, by replacement the fallowing inequality is
obtained:
[(Ai − I)Q +BiKjQ]1
n ≪ 0,
[(Ai − I) +BiKj]Q1
n ≪ 0,
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By definition p , Q1n and by using Proposition (1), one can conclude that the system (14) is
asymptotically stable. Now, the condition (15d) implies that the closed-loop system (14) is positive,
since
[
ai
]
h t
+
r∑
z=1
[
bi
]
h z
[
mj
]
z t
q−1t = (Ai +BiKj)ht ≥≥ 0.
Necessity: Assume that system (14) is asymptotically stable. In (10), Ai is replaced by the
closed-loop system matrix (Acl = Ai + BiKj). Now, the Lyapunov vector p is defined in the form
of:
p = Q1n, Q = diag(q1, q2, ..., qn)≫ 0. (17)
Now, inequality (10) can be rewritten as follows:
(Ai +BiKj − I)Q1
n ≪ 0,
[(Ai − I)Q+BiKjQ]1
n ≪ 0. (18)
By definition Mj , KjQ, (18) is equivalent to (15a). To show that the trajectories remain in the
positive orthant for all k ∈ Rn+, the following inequality should be satisfied:
(Ai +BiKj)ht ≥≥ 0. (19)
By post-multiplying (19) by the matrix Q = diag(q1, q2, ..., qn) ≫ 0, and using definitions Ai ,[
ai
]
ht
and Bi ,
[
bi
]
ht
, the following result is obtained:
(Ai +BiKj)htQ ≥≥ 0,
(AiQ)ht + (B
iKjQ)ht ≥≥ 0. (20)
Now, by using definition
(
Kj Q
)
ht
,
(
M j
)
ht
=
[
mj
]
ht
, the equation (20) can be rewritten as:
[
ai
]
h t
qt +
r∑
z=1
[
bi
]
h z
[
mj
]
z t
≥≥ 0, h, t = 1, ..., n. (21)
Inequality (21) is equivalent to (15d). Thus, the proof is complete. 
Remark 2. The obtained results provide not only necessary and sufficient conditions but also
there are simple approaches that can lead to a numerical solution for the problem. In fact, since
the functions corresponding to the inequality constraints are all linear, the optimization problem
can be considered in the standard LPs framework.
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Remark 3. From the biological point of view, the asymptotic stability of the system based on
negativity of the Lyapunov function derivative in Theorem (1) states that the number of tumor
cells is moving towards the equilibrium, which indicates that this state is transferred from the
malignant region or macroscopic tumor volume into the region of benign growth or microscopic
tumor volume, in which the immune system is able to inhibit the tumor growth. Therefore, the
side effects of treatment can be significantly reduced. Moreover, based on the same argument, the
number of effector cells of the immune system attains a proper level, in which the bodys immune
system would be able to start eliminating cancer cells. In addition, it should be noted that according
to inequalities (15d) the positivity of the states is preserved, which guarantees the positivity of the
number of tumor and effector cells. This constraint has to be satisfied since from the biological
view the number of tumor and effector cells cannot be negative.
4. Simulation results
In this section, a simulation study is performed to show the efficiency of the proposed positive
fuzzy controller for interactions of the tumor-immune system under immunotherapy and chemother-
apy. Accordingly, a numerical simulation is carried out through MATLAB software. Consider
system (6) with matrices Ai and Bi, i = 1, ..., 8 as shown below:
A 1 =

5.01780 0
0 −0.3740

 , B 1 =

−0.100 0
0 1

 ,
A 2 =

5.01780 0
0 −0.3740

 , B 2 =

−1000 0
0 1

 ,
A 3 =

5.01780 0
0 −8.3121

 , B 3 =

−0.100 0
0 1

 ,
A 4 =

5.01780 0
0 −8.3121

 , B 4 =

−1000 0
0 1

 ,
A 5 =

−5.1391 0
0 −0.3740

 , B 5 =

−0.100 0
0 1

 ,
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A 6 =

−5.1391 0
0 −0.3740

 , B 6 =

−1000 0
0 1

 ,
A 7 =

−5.1391 0
0 −8.3121

 , B 7 =

−0.100 0
0 1

 ,
A 8 =

−5.1391 0
0 −8.3121

 , B 8 =

−1000 0
0 1

 .
As it can be seen, matrices Ai and Bi are not positive, however, the matrix C = I2 is common
for all the configurations. A controller system is designed for the augmented system to prevent the
progression of cancer, while ensuring the positiveness of state variables. Accordingly, the conditions
of Theorem (1) are applied. By solving the set of LPs in Eq. (15a)-(15d), the state-feedback
controller gain, and the closed-loop matrices are achieved as follows:
K1 =

 0.0329 0.0000
5.0758 −1.5236

 , K2 =

−0.0018 0.0000
5.3526 −1.4356


K3 =

 0.0010 0.0000
5.3542 −1.4356

 , K4 =

 0.0010 0.0000
5.3377 −1.4356


K5 =

−0.0047 0.0000
5.3460 −1.4356

 , K6 =

 0.0022 0.0000
5.3493 −1.4356


K7 =

 0.0011 0.0000
5.4053 −1.4777

 , K8 =

 0.0455 0.0000
5.4152 −1.4777


A1 =

1.6512 0.0000
0.4982 0.8137

 , A2 =

1.8790 0.0000
0.5254 0.8224


A3 =

1.6516 0.0000
0.3636 0.3380

 , A4 =

1.5179 0.0000
0.3625 0.3380


A5 =

0.5982 0.0000
0.5247 0.8224

 , A6 =

0.4291 0.0000
0.5250 0.8224


A7 =

0.5981 0.0000
0.3671 0.3352

 , A8 =

1.6900 0.0000
0.3677 0.3352


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The trajectories of state x1 and x2 and the corresponding control inputs are depicted in Figs.
2-4 for a 60 days of the treatment when the proposed positive fuzzy control is applied to the system.
The reference and initial conditions are selected within zr =
[
50 1.6
]T
and X0 =
[
600 0.1
]T
.
Figure 2 depicts the effect of chemotherapy in the cancer treatment. Although the cancer
treatment under exclusive chemotherapy has the ability to control the growth of cancer cells, the
immediate alteration of chemotherapy dose rate is necessary for the purpose of treatment. Figure
3 exclusively illustrates the effect of immunotherapy in treating cancer. There is evidently a failed
cancer treatment. In fact, in cases where the initial condition is located in the malignant region,
the immune system can not prevent the progression of cancer, and, thus, the tumor growths un-
controllably. A combination therapy that is fundamental to a successful treatment, under mixed
immunotherapy and chemotherapy is demonstrated in fig. 4. As observed by applying the sug-
gested controller, the tumor load reduces and converges to the equilibrium in the benign region
and the number of effector cells attains a proper level after only 20 days upon starting the im-
munotherapy and chemotherapy treatments. These results are a major success in recovering the
control approaches for the cancer therapy.
Compared to the results of Ref. [24] that was accomplished on the same model used in this
article, with the similar initial condition X0 =
[
600 0.1
]T
, it is seen that the designed controller
in the current work is able to eliminate more tumor cells and also guarantees the positiveness of the
closed-loop system in such a way that no positive constraints imposed to the variables. Additionally,
the amplitude of the control inputs in this approach is lower than the one in [24]. In general, a
maximum of 20 % of the full dose rate of the drug is approximately needed to control the progression
of cancer. Accordingly, less control efforts are required for the cancer treatment and, consequently,
the side effects of the treatment are reduced significantly. It should be noted that the maximum
amount of cancer cells in the proposed method is much lower than the one in [24], which indicates a
reduction in the likelihood of death during the course of treatment. In other words, by considering
the initial condition X0 =
[
600 0.1
]T
that belongs to the malignant status of the tumor, the
proposed controller is an efficient tool for the goal of treatment.
5. Conclusion
This paper suggests a new fuzzy modeling approach for the nonlinear modified Stepanovas
model, which is one of the efficient and applicable models for the cancer treatment. In spite of
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Figure 2: The effect of chemotherapy (u1).
the previous works that used optimal control strategies, this paper proposes a positive T–S fuzzy
controller for the successful treatment of cancer under mixed immunotherapy and chemotherapy.
This is based on a new framework that incorporates, for the first time, T–S fuzzy model, linear
co-positive Lyapunov function, and parallel distributed compensation via a convex optimization
approach. This new framework is a lot invaluable since there are inherent nonnegative sign features
for the state variables and their corresponding control inputs. The simulation results show that
the control structure can be successfully exploited to the tumor-immune system, which leads to the
best performance in the sense that it significantly minimizes the volume of the tumor cells and,
consequently, reduces the doses of the consumed drug. However, the population of the immune
competent cells can reach an appropriate level, so that the immune system can prevent tumor
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Figure 3: The effect of immunotherapy (u2).
growth. Future research will concern an extension of this method to the design of a controller
considering uncertainties, disturbance, and unknown factors in the nonlinear model. The proposed
methodology can also be applied in treating other specific types of cancer.
Appendix A. A review on fuzzy systems and positive systems
In this section, brief reviews of T–S fuzzy systems and positive systems are provided. More-
over, several observations and results associated with the positive T–S fuzzy systems that are used
throughout this paper are introduced. The T–S fuzzy system is one of the most widely used ap-
proaches for the stability analysis and controller design of nonlinear systems [15]. Explicitly, the
T–S fuzzy model is described by fuzzy IF-THEN rules, where each locally characterizes linear
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Figure 4: The effect of chemotherapy and immunotherapy.
input-output relations of the system through the sector nonlinearity technique.
Assume the ith plant rule of the T–S model is as follows:
Plant rule i: IF ϑ1(k) is Mi1 and, ..., and ϑn(k) is Min , THEN


x(k + 1) = Aix(k) +Biu(k),
z(k) = Cix(k) +Diu(k),
x(0) = x0  0,
(A.1)
where x(k) ∈ Rn, u(k) ∈ Rm, and z(k) ∈ Rl are the state vector, input vector, and output vector,
respectively. i ∈ ℧r = {1, ..., r}, r is the number of IF-THEN rules. ϑ1(k), ..., ϑn(k) and Mij are
the premise variables and the membership functions, respectively. Then, the overall T–S model is
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given by:
S :


x(k + 1) =
r∑
i=1
hi(ϑ(k))(Aix(k) +Biu(k),
z(k) =
r∑
i=1
hi(ϑ(k))(Cix(k) +Diu(k),
x(0) = x0  0,
(A.2)
where
hi(ϑ(k)) =
ωi(ϑ(k))∑r
i=1 ωi(ϑ(k))
, ωi(ϑ(k)) =
µ∏
j=1
Mij(ϑj(k)),
r∑
i=1
hi(ϑ(k)) = 1, 0 ≤ hi(ϑ(k)) ≤ 1,
and Mij(ϑj(k)) is the grade of membership of ϑj(k) in Mij .
Here, the essential definitions and lemma are introduced.
Definition 1. [17]: Given any positive initial condition x(0) ≥≥ 0 and input u(k) ≥≥ 0, the
discrete-time system (A.2) is said to be positive if x(k) ≥≥ 0 and z(k) ≥≥ 0 for all integers
k ∈ Rn+.
Definition 2. [17]: In the continuous-time system, a real matrix A is called a Metzler matrix if its
off-diagonal elements are positive, i.e. Aij ≥ 0, i 6= j.
Definition 3. [17]: In the discrete-time system, a real matrix A is called Schur if all its eigenvalues
are strictly inside the unit circle.
Definition 4. A linear map V (x(k)) = pTx(k) with V (0) = 0 is said to be an LCPLF for positive
system x(k + 1) = Ax(k), if the following conditions hold for all x ∈ Rn+:

V (x(k)) > 0,
∆V (x(k)) < 0.
Lemma 1. [16]: The discrete-time T–S fuzzy system (A.2) is positive if and only if
Ai ≥≥ 0, Bi ≥≥ 0, Ci ≥≥ 0, Di ≥≥ 0,
where i = 1, ..., r.
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Remark 4. When x(0) ∈ Rn+ is not hold, x(k) ≥≥ 0, may not satisfy for all the sets of nonnegative
integers even if all the conditions of Lemma (1) hold. In order to certify the advisable efficiency of
Lemma (1), the satisfaction of x(0) ∈ Rn+ is assumed.
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